Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Blood (2024) 143 (16): 1565–1575.

https://doi.org/10.1182/blood.2023022432

Published: 2024

Journal Articles

A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Peter A. Riedell, Jamie Brower, Loretta Nastoupil, Miguel-Angel Perales, Richard T. Maziarz, Joseph P. McGuirk, Veronika Bachanova, Wei-Ting Hwang, Stephen J. Schuster, Michael R. Bishop, David L. Porter

Blood (2021) 138 (Supplement 1): 2512.

https://doi.org/10.1182/blood-2021-151971

Published: 2021

Journal Articles

Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Blood (2021) 138 (Supplement 1): 3826.

https://doi.org/10.1182/blood-2021-147488

Published: 2021

Journal Articles

Evaluation of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Database Analysis

Danny Luan, Christopher R. Flowers, Brian K. Link, Jonathan W. Friedberg, Jonathon B. Cohen, Brad S. Kahl, Izidore S. Lossos, Loretta Nastoupil, Matthew J. Maurer, James R. Cerhan, Peter Martin

Blood (2021) 138 (Supplement 1): 338.

https://doi.org/10.1182/blood-2021-146099

Published: 2021

Journal Articles

A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies

Elizabeth Budde, Ajay K Gopal, Won Seog Kim, Ian W. Flinn, Chan Yoon Y. Cheah, Loretta Nastoupil, Matthew J. Matasar, Catherine S. Diefenbach, Gareth P Gregory, Ibrahim Qazi, Ching-Fai Pang, Maya Leabman, Genevive Hernandez, Iris Sison, Bruce A. Keyt, Daniel Chen, Philippe Armand

Blood (2021) 138 (Supplement 1): 132.

https://doi.org/10.1182/blood-2021-153355

Published: 2021

Journal Articles

Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

Blood (2021) 138 (Supplement 1): 131.

https://doi.org/10.1182/blood-2021-145025

Published: 2021

Journal Articles

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

Blood (2021) 138 (Supplement 1): 127.

https://doi.org/10.1182/blood-2021-145872

Published: 2021

Journal Articles

A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 38.

https://doi.org/10.1182/blood-2021-148314

Published: 2021

Journal Articles

Phase II Trial of Response Adapted Ultra Low Dose (ULD) Orbital Radiation Therapy for Indolent B Cell Lymphoma

Blood (2021) 138 (Supplement 1): 3526.

https://doi.org/10.1182/blood-2021-154172

Published: 2021

Journal Articles

Ten Year Follow up of the MD Anderson Cancer Center Phase 2 Study of Rituximab in Combination with Lenalidomide (R2) for Patients with Low Tumor Burden Follicular Lymphoma

Dai Chihara, Loretta Nastoupil, Paolo Strati, Felipe Samaniego, Lei Feng, Maria Alma Rodriguez, Luis Fayad, Jason R. Westin, Fredrick B. Hagemeister, Michael Wang, Sattva S. Neelapu, Nathan H. Fowler

Blood (2021) 138 (Supplement 1): 3532.

https://doi.org/10.1182/blood-2021-149293

Published: 2021

Journal Articles

Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study

Jean-Marie Michot, Julio C. Chavez, Cecilia Carpio, Silvia Ferrari, Tatyana A. Feldman, Daniel Morillo, John Kuruvilla, Antonio Pinto, Vincent Ribrag, Emmanuel Bachy, Tonia J Buchholz, Soraya Carrancio, Carla Guarinos, Fan Wu, Shaoyi Li, Poliana Patah, Michael Pourdehnad, Loretta Nastoupil

Blood (2021) 138 (Supplement 1): 3574.

https://doi.org/10.1182/blood-2021-147333

Published: 2021

Journal Articles

Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2 ) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance

Blood (2021) 138 (Supplement 1): 2417.

https://doi.org/10.1182/blood-2021-148218

Published: 2021

Journal Articles

Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

Connie Lee Batlevi, Steven I. Park, Loretta Nastoupil, Tycel Phillips, Jennifer E. Amengual, David Andorsky, Philip Campbell, Pamela McKay, John M. Pagel, John P. Leonard, Jay Yang, Heather O'Connor, Anthony Hamlett, Deyaa Adib, Franck Morschhauser

Blood (2021) 138 (Supplement 1): 2207.

https://doi.org/10.1182/blood-2021-148199

Published: 2021

Journal Articles

Long Term Outcome Patterns and Risk Factors for Early Mortality and Disease Progression in ALK-Positive Anaplastic Large Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2463.

https://doi.org/10.1182/blood-2021-150798

Published: 2021

Journal Articles

Outcomes of Aggressive B Cell Lymphoma Patients with No Evidence of Measurable Disease at the Time of CD19 Chimeric Antigen Receptor T Cell Therapy: The Experience from the CAR T Cell Consortium

Kitsada Wudhikarn, Ana Alarcon Tomas, Jamie Brower, Veronika Bachanova, Richard T. Maziarz, Joseph P. McGuirk, Loretta Nastoupil, David L. Porter, Peter A. Riedell, Miguel-Angel Perales

Blood (2021) 138 (Supplement 1): 2843.

https://doi.org/10.1182/blood-2021-150012

Published: 2021

Journal Articles

Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma Patients in Complete Metabolic Response at Time of Infusion

Blood (2021) 138 (Supplement 1): 1740.

https://doi.org/10.1182/blood-2021-145503

Published: 2021

Journal Articles

Real World Evidence (RWE) of Safety, Efficacy, and Outcomes of CD19 CAR-T Therapy in 20 Patients with Solid Organ Transplant (SOT)-Related Post-Transplant Lymphoproliferative Disorder (PTLD)

Jieqi Liu, Epperla Narendranath, Armin Ghobadi, Aleksandr Lazaryan, Uroosa Ibrahim, Caron Jacobson, Seema G Naik, Adam J. Olszewski, Yong Lin, Sayan Mullick Chowdhury, Miriam T. Jacobs, Loretta Nastoupil, Keren Osman, Sairah Ahmed, Andrew M. Evens

Blood (2021) 138 (Supplement 1): 3853.

https://doi.org/10.1182/blood-2021-149786

Published: 2021

Journal Articles

Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR after CAR T-Cell Therapy

Ajlan Al Zaki, Jason R. Westin, Grace Watson, Lei Feng, Sairah Ahmed, Haleigh Mistry, Loretta Nastoupil, Misha Hawkins, Ranjit Nair, Swaminathan P Iyer, Hun Lee, Raphael E Steiner, Christopher R. Flowers, Elizabeth J. Shpall, Partow Kebriaei, Sattva S. Neelapu, Paolo Strati

Blood (2021) 138 (Supplement 1): 3870.

https://doi.org/10.1182/blood-2021-146023

Published: 2021

Journal Articles

Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series

Blood (2021) 138 (Supplement 1): 4536.

https://doi.org/10.1182/blood-2021-154347

Published: 2021

Journal Articles

Pacific: A Phase II Study of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma

Raphael E Steiner, Paolo Strati, Christopher R. Flowers, Sattva S. Neelapu, Michael R Green, Loretta Nastoupil, Fredrick B. Hagemeister, Lei Feng, Sairah Ahmed, Ranjit Nair, Luis Fayad, Hun Ju Lee, Maria Alma Rodriguez, Jason R. Westin

Blood (2021) 138 (Supplement 1): 1408.

https://doi.org/10.1182/blood-2021-149616

Published: 2021

NARROW

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Evaluation of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Database Analysis

A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies

Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma

Phase II Trial of Response Adapted Ultra Low Dose (ULD) Orbital Radiation Therapy for Indolent B Cell Lymphoma

Ten Year Follow up of the MD Anderson Cancer Center Phase 2 Study of Rituximab in Combination with Lenalidomide (R2) for Patients with Low Tumor Burden Follicular Lymphoma

Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study

Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2 ) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance

Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

Long Term Outcome Patterns and Risk Factors for Early Mortality and Disease Progression in ALK-Positive Anaplastic Large Cell Lymphoma

Outcomes of Aggressive B Cell Lymphoma Patients with No Evidence of Measurable Disease at the Time of CD19 Chimeric Antigen Receptor T Cell Therapy: The Experience from the CAR T Cell Consortium

Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma Patients in Complete Metabolic Response at Time of Infusion

Real World Evidence (RWE) of Safety, Efficacy, and Outcomes of CD19 CAR-T Therapy in 20 Patients with Solid Organ Transplant (SOT)-Related Post-Transplant Lymphoproliferative Disorder (PTLD)

Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR after CAR T-Cell Therapy

Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series

Pacific: A Phase II Study of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only